Question · Q3 2025
Aaron inquired about the growth of esoteric testing (almost double routine), how R&D investments are prioritized for these tests, and the commercialization strategy and reimbursement updates for Genoscopy's ColoSense.
Answer
Chairman and CEO Adam Schechter noted continued asymptotic increases in esoteric testing, which, while lower volume, are important for driving routine tests. Labcorp focuses R&D on high-growth specialty areas like oncology, women's health, neurology, and autoimmune diseases, expecting 2-3x market growth. He stated Labcorp is agnostic to internal development versus licensing/acquiring to bring the best tests to market quickly. Specific ColoSense commercialization or reimbursement details were not provided.
Ask follow-up questions
Fintool can predict
LH's earnings beat/miss a week before the call